Ventilator-Associated Pneumonia

In Nepal, Thailand and Singapore, an individualized short antibiotic course vs. usual care was estimated to be cost effective for the treatment of ventilator-associated pneumonia, according to findings published in The Lancet Global Health.

An individualized short antibiotic course was non-inferior to usual care in those with ventilator-associated pneumonia when assessing mortality and pneumonia recurrence at day 60, according to study results.

One dose of ceftriaxone lowered the risk for ventilator-associated pneumonia within the first week of mechanical ventilation among patients with acute brain injury, according to results published in The Lancet Respiratory Medicine.

Fewer critically ill adults who received inhaled amikacin vs. placebo for 3 days developed ventilator-associated pneumonia by day 28, according to results published in The New England Journal of Medicine.

Time to successful weaning off of extracorporeal membrane oxygenation was similar for prone and supine positioning among patients with severe acute respiratory distress syndrome, according to results published in JAMA.

BOSTON — Aztreonam-avibactam was shown to be effective in the treatment of hospitalized adults who were critically ill with multidrug-resistant, gram-negative bacterial infections, according to the results of the phase 3 REVISIT trial.